The Wall Street Journal: New omicron-specific COVID booster expected to be approved before trial data is in


The Food and Drug Administration is expected to authorize new COVID-19 booster shots this week without a staple of its normal decision-making process: data from a study showing whether the shots were safe and worked in humans.

The shots, modified to target the latest versions of the omicron variant, won’t have finished testing in humans when the FDA makes its decisions.

This article was originally published by Read the original article here.

Previous article: ‘All of this puts parents in a pickle’: A sharp rise in lunch-meat prices adds to parents’ back-to-school stress
Next articleU.S. stock futures sink following Friday’s Wall Street rout


Please enter your comment!
Please enter your name here